BridgeBio Pharma, Inc.
BBIOHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframeBridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The $12.98B market capitalization puts BBIO squarely in large-cap range for its industry. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.
Market Cap
$12.98B
Beta
1.02
P/E (TTM)
—
P/E (Fwd)
199.92
EPS (TTM)
$-3.74
EPS (Fwd)
$0.33
ROE
—
ROA
-28.0%
Cash
$940.2M
Total Debt
$2.49B
Free CF
-$317.9M
52W Change
86.9%
Annual Financials
Cash vs Debt
BridgeBio Pharma, Inc. carries $2.49B in total debt against $940.2M in cash reserves — debt is roughly 2.7x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$317.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has grown from $77.6M (2022) to $502.1M (2025), reflecting a 547% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence BridgeBio Pharma, Inc.'s trajectory.